Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
Illumina, Inc.
IndexS&P 500 P/E58.13 EPS (ttm)5.39 Insider Own0.40% Shs Outstand147.00M Perf Week-3.83%
Market Cap46.07B Forward P/E51.06 EPS next Y6.14 Insider Trans-14.78% Shs Float146.37M Perf Month-11.25%
Income798.00M PEG2.68 EPS next Q1.26 Inst Own92.30% Short Float1.65% Perf Quarter2.59%
Sales3.10B P/S14.85 EPS this Y89.40% Inst Trans0.32% Short Ratio2.50 Perf Half Y26.13%
Book/sh22.16 P/B14.14 EPS next Y12.58% ROA11.90% Target Price349.13 Perf Year51.46%
Cash/sh17.09 P/C18.34 EPS next 5Y21.69% ROE21.80% 52W Range198.21 - 372.61 Perf YTD43.44%
Dividend- P/FCF61.26 EPS past 5Y39.20% ROI9.90% 52W High-12.75% Beta1.08
Dividend %- Quick Ratio2.40 Sales past 5Y19.10% Gross Margin68.90% 52W Low64.03% ATR9.47
Employees6200 Current Ratio2.70 Sales Q/Q25.40% Oper. Margin27.60% RSI (14)43.44 Volatility3.41% 2.38%
OptionableYes Debt/Eq0.41 EPS Q/Q62.20% Profit Margin20.90% Rel Volume1.62 Prev Close313.41
ShortableYes LT Debt/Eq0.22 EarningsOct 23 AMC Payout0.00% Avg Volume965.24K Price325.12
Recom1.90 SMA20-5.60% SMA50-5.02% SMA20016.65% Volume1,134,864 Change3.74%
Oct-09-18Initiated UBS Neutral
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Sep-26-17Resumed Goldman Neutral $200
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Oct-16-18 10:31AM  Illumina (ILMN) Q3 Earnings Preview: What's in the Cards? Zacks
Oct-15-18 11:11AM  Is Now An Opportune Moment To Examine Illumina Inc (NASDAQ:ILMN)? Simply Wall St.
Oct-11-18 05:45PM  Illumina (ILMN) Gains As Market Dips: What You Should Know Zacks
04:02PM  12 Vulnerable Stocks to Watch on Market-Wide Weakness Kiplinger
07:55AM  Analysis: Positioning to Benefit within Tenet Healthcare, GAIN Capital, Illumina, First Cash, Regis, and Cornerstone OnDemand Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-09-18 04:30PM  Illumina to Announce Third Quarter 2018 Financial Results on Tuesday, October 23, 2018 Business Wire
Oct-08-18 08:00AM  Growth Stocks That Fuel This Mutual Fund Manager's Outperformance Investor's Business Daily
Oct-05-18 03:02PM  Stocks Today: Tesla, Costco Hit As Nasdaq Extends Losses; 10-Year Yield Up Again Investor's Business Daily
10:11AM  Stocks Volatile After Jobs Report; This Retailer Breaks Support Investor's Business Daily
08:46AM  Share Your DNA, Get Shares: Startup  Files an Unusual Offering Bloomberg
Oct-04-18 09:35AM  Staring down IP theft lawsuit, synthetic biology company seeks $86M IPO American City Business Journals
Oct-02-18 10:10AM  Why Illumina (ILMN) Could Beat Earnings Estimates Again Zacks
Oct-01-18 08:07AM highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM Zacks
Sep-28-18 09:30AM  Has Illumina (ILMN) Outpaced Other Medical Stocks This Year? Zacks
09:00AM  Illumina Announces Conversion Period for 0% Convertible Senior Notes due 2019 and 0.5% Convertible Senior Notes due 2021 Business Wire
08:02AM  Looking for Earnings Beat? Play These Top 5 Stocks Zacks
07:31AM  3 Stocks to Hold for the Next 20 Years Motley Fool
Sep-26-18 08:41AM  Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher Zacks
Sep-25-18 11:43AM  5 Companies Hit 52-Week Highs
Sep-20-18 09:37AM  This fast-growing Bay Area tech company pays its typical worker more than $256,000 and it's not Facebook, Google or Intel American City Business Journals
Sep-18-18 08:50AM  Cytori's Chemotherapy Candidate Gets Orphan Drug Status Zacks
Sep-14-18 02:34PM  AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology Zacks
09:09AM  The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion Zacks
08:37AM  DENTSPLY Launches Azento, Improves Digital Implant Workflow Zacks
Sep-13-18 09:14AM  IPOs and Foreign Investment Propel Biotech: 4 Top Picks Zacks
07:46AM  Allscripts' Sunrise Abstracting Selected by Wyckoff Heights Zacks
Sep-12-18 09:30AM  Is Illumina (ILMN) Stock Outpacing Its Medical Peers This Year? Zacks
07:47AM  Here's Why You Should Hold On to DaVita (DVA) Stock Now Zacks
Sep-11-18 02:16PM  Why Pacific Biosciences Fell By 10.6% Earlier Today Motley Fool
Sep-08-18 05:52PM  Two more Peninsula IPOs tell the story of biotech's investment boom American City Business Journals
Sep-07-18 03:13PM  How Has Illumina Incs (NASDAQ:ILMN) Earnings Fared Against The Long Term Trend Simply Wall St.
Sep-06-18 12:33PM  How This Player Helps Medical Researchers Ease Drug Discovery Process Investor's Business Daily
Sep-05-18 11:12AM  MannKind Stock Up on Licensing Deal With United Therapeutics Zacks
09:00AM  Inscripta Announces Strategic Acquisition of Solana Biosciences PR Newswire
08:00AM  HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates Zacks
Sep-04-18 10:02AM highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries Zacks
Sep-03-18 09:06AM  Wall Street Witnesses the Best August in 4 Years: 5 Top Picks Zacks
Aug-31-18 01:28PM  One sector is beating tech this quarter, but one technician sees a ceiling CNBC
10:08AM  4 of the Best Efficient Stocks to Enrich Your Portfolio Zacks
09:41AM  Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3 Zacks
Aug-30-18 04:05PM  Illumina to Webcast Upcoming Investor Conference Presentation Business Wire
03:41PM  Affimed (AFMD) Surges on Collaboration Contract with Roche (revised) Zacks
10:39AM  AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon Zacks
09:34AM  Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost Zacks
08:35AM  Patterson Companies (PDCO) Misses Q1 Earnings Estimates Zacks
Aug-29-18 11:31AM  Why Is Illumina (ILMN) Up 6.3% Since Last Earnings Report? Zacks
11:20AM  Affimed (AFMD) Surges On Collaboration Contract With Roche Zacks
11:15AM featured highlights include: Columbia Sportswear, Illumina, WellCare, athenahealth and Caterpillar Zacks
08:43AM  Increased Earnings Estimates Seen for Illumina (ILMN): Can It Move Higher? Zacks
Aug-28-18 05:45PM  Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks
02:33PM  5 Top Stocks Likely to Beat Earnings Estimates InvestorPlace
12:22PM  Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y Zacks
11:39AM  Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis Zacks
11:00AM  SoftBank-backed 10x Genomics makes a clever buy to help unlock the human biological code CNBC
10:40AM  Nasdaq ETF Hits New Highs: 5 Stocks Up More Than 50% Zacks
10:14AM  5 Top Stocks Likely to Beat Earnings Estimates Zacks
08:33AM featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina Zacks
08:13AM  The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic Benzinga
Aug-27-18 04:05PM  Illumina Receives Approval of MiSeqDx System in China Business Wire
09:21AM  5 Momentum Stocks Worth Investing in via Driehaus Strategy Zacks
08:56AM  Indexes Close at Record High as Markets Move North: 5 Picks Zacks
Aug-24-18 06:58PM  Here's Why You Should Invest in Integer (ITGR) Stock Now Zacks
09:23AM  Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates Zacks
Aug-23-18 10:54AM  Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer Zacks
09:42AM  Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks
09:05AM  Better Buy: Illumina (ILMN) vs. Roche (RHHBY) Motley Fool
Aug-22-18 09:01AM  Bull Market Set to Become Longest in History: 5 Picks Zacks
08:46AM  Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4 Zacks
Aug-21-18 11:15AM  Alexion's BLA for ALXN1210 Gets Priority Review From FDA Zacks
10:13AM  Medtronic (MDT) Q1 Earnings Beat on Growth in All Lines Zacks
Aug-20-18 11:10AM  Roche's Lung Cancer Drug Alecensa Gets Approval in China Zacks
08:45AM highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International Zacks
Aug-17-18 09:44AM  4 Winning Stocks With Solid Efficiency Level Zacks
09:12AM  Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA Zacks
Aug-16-18 08:28PM  Illumina Announces Pricing of Convertible Senior Notes Business Wire
Aug-15-18 04:15PM  Illumina to Offer $650 Million Convertible Senior Notes Business Wire
Aug-14-18 06:13PM  Will This Biotech Stock Join the $1,000 Human Genome Club in Early 2019? Motley Fool
08:33AM  Can Illumina (ILMN) Stock Continue to Grow Earnings? Zacks
Aug-10-18 08:07PM  Here's Why CareDx Jumped 13.5% Today Motley Fool
06:45PM  Why Illumina, Inc. Stock Popped 16.1% in July Motley Fool
Aug-09-18 11:48AM  PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y Zacks
09:20AM  OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2 Zacks
09:10AM  Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View Zacks
Aug-08-18 01:01PM  IBD 50 Growth Stocks To Watch Investor's Business Daily
09:30AM  CBM vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
08:34AM  Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance Zacks
07:54AM  Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View Zacks
Aug-07-18 11:43AM  Market, Policy Trends Are Shifting In Illumina's Favor, Morgan Stanley Says In Upgrade Benzinga
10:24AM  DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance Zacks
08:57AM  Dow Jones Leads Stocks Higher As Disney Jumps, Global Markets Rally Investor's Business Daily
08:50AM  Luminex (LMNX) Misses on Earnings in Q2, Margins Contract Zacks
Aug-06-18 04:00PM  This stock sector most often beats analysts estimates MarketWatch
02:04PM  Illumina CEO on the growth of DNA sequencing CNBC Videos
09:27AM  Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates Zacks
08:52AM  Cardinal Health (CAH) Surpasses Earnings Estimates in Q4 Zacks
08:20AM  Detailed Research: Economic Perspectives on Allete, Sterling Construction, Illumina, PROS, Altra Industrial Motion, and Pacific Biosciences of California What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-03-18 05:36PM  Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates Zacks
04:58PM  Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y Zacks
12:35PM  8 Bargain Stocks With Big Upside Potential Investopedia
09:58AM  Pacific Biosciences (PACB) Loss In Line With Estimates in Q2 Zacks
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ronaghi MostafaSr VP & CTOOct 10Option Exercise37.0410,000370,40080,805Oct 12 04:37 PM
Ronaghi MostafaSr VP & CTOOct 10Sale311.8410,0003,118,42470,805Oct 12 04:37 PM
FLATLEY JAY TDirectorOct 10Sale321.583,3001,061,214385,604Oct 12 04:35 PM
EPSTEIN ROBERT SDirectorOct 01Option Exercise51.171,00051,1706,793Oct 03 04:17 PM
deSouza Francis APresident and CEOOct 01Sale369.612,100776,18372,335Oct 03 04:20 PM
EPSTEIN ROBERT SDirectorOct 01Sale369.151,346496,8765,447Oct 03 04:17 PM
FLATLEY JAY TDirectorSep 26Sale360.813,3001,190,673388,904Sep 28 05:29 PM
FLATLEY JAY TDirectorSep 12Sale351.663,3001,160,478392,204Sep 14 09:25 PM
Ronaghi MostafaSr VP & CTOSep 10Option Exercise37.0410,000370,40080,805Sep 11 05:49 PM
Ronaghi MostafaSr VP & CTOSep 10Sale347.0710,0003,470,70970,805Sep 11 05:49 PM
EPSTEIN ROBERT SDirectorSep 07Option Exercise51.171,00051,1707,139Sep 11 05:45 PM
EPSTEIN ROBERT SDirectorSep 07Sale345.141,346464,5585,793Sep 11 05:45 PM
deSouza Francis APresident and CEOSep 04Sale353.662,100742,68674,435Sep 06 06:26 PM
Van Oene MarkSVP Chief Commercial OfficerSep 04Sale354.181,091386,41011,126Sep 06 06:09 PM
Stapley MarcEVP Strategy & Corp DevelopmtSep 04Sale352.051,000352,0548,516Sep 06 08:22 PM
Ronaghi MostafaSr VP & CTOAug 10Option Exercise37.0410,000370,40080,805Aug 14 04:07 PM
Ronaghi MostafaSr VP & CTOAug 10Sale331.3910,0003,313,86170,805Aug 14 04:07 PM
OSTADAN OMEADEVP Ops, Products, StrategyAug 02Sale320.701,334427,81424,484Aug 06 08:11 PM
Stapley MarcEVP Strategy & Corp DevelopmtAug 02Sale324.801,000324,7987,516Aug 06 08:10 PM
deSouza Francis APresident and CEOAug 01Sale327.412,100687,55576,535Aug 03 03:03 PM
EPSTEIN ROBERT SDirectorJul 23Sale311.15500155,5756,139Jul 24 07:21 PM
deSouza Francis APresident and CEOJul 12Sale300.003,300990,00078,635Jul 13 02:39 PM
Ronaghi MostafaSr VP & CTOJul 10Option Exercise37.047,500277,80078,496Jul 12 07:39 PM
Ronaghi MostafaSr VP & CTOJul 10Sale288.897,5002,166,70170,996Jul 12 07:39 PM
deSouza Francis APresident and CEOJul 02Sale276.142,100579,88782,271Jul 03 06:20 PM
EPSTEIN ROBERT SDirectorJun 21Sale288.45500144,2256,639Jun 22 07:12 PM
Ronaghi MostafaSr VP & CTOJun 11Option Exercise28.4510,500298,72581,496Jun 13 06:21 PM
Stapley MarcEVP Strategy & Corp DevelopmtJun 11Sale285.181,446412,3648,516Jun 13 06:24 PM
Ronaghi MostafaSr VP & CTOJun 11Sale284.8310,5002,990,75970,996Jun 13 06:21 PM
OSTADAN OMEADEVP Ops, Products, StrategyJun 01Sale274.611,335366,60425,818Jun 04 08:57 PM
deSouza Francis APresident and CEOJun 01Sale272.912,100573,10784,371Jun 04 08:54 PM
EPSTEIN ROBERT SDirectorMay 21Sale271.00500135,5006,588May 22 05:25 PM
EASTHAM KARINDirectorMay 21Sale269.801,000269,80212,288May 22 05:23 PM
Ronaghi MostafaSr VP & CTOMay 16Option Exercise28.4510,000284,50080,996May 18 07:39 PM
Ronaghi MostafaSr VP & CTOMay 16Sale267.7110,0002,677,13570,996May 18 07:39 PM
FLATLEY JAY TDirectorMay 14Sale268.001,460391,2804,000May 16 09:40 PM
deSouza Francis APresident and CEOMay 14Sale268.632,100564,12486,471May 16 09:37 PM
OSTADAN OMEADEVP Ops, Products, StrategyMay 02Sale242.601,314318,77627,153May 04 06:53 PM
BOWMAN A BLAINEDirectorMay 01Option Exercise55.143,000165,42619,868May 03 06:23 PM
BOWMAN A BLAINEDirectorMay 01Sale241.453,000724,33616,868May 03 06:23 PM
Van Oene MarkSVP Chief Commercial OfficerApr 12Sale238.481,400333,87212,217Apr 13 07:30 PM
Dadswell CharlesSr VP & General CounselApr 03Sale230.9111626,7867,875Apr 04 07:32 PM
BOWMAN A BLAINEDirectorApr 02Option Exercise44.513,000133,53019,868Apr 04 07:29 PM
BOWMAN A BLAINEDirectorApr 02Sale230.133,000690,38316,868Apr 04 07:29 PM
ARNOLD FRANCESDirectorMar 15Sale252.2625063,06510,189Mar 15 07:56 PM
ARNOLD FRANCESDirectorMar 08Sale241.5025060,37510,439Mar 08 07:50 PM
Stapley MarcEVP Strategy & Corp DevelopmtMar 06Sale233.642,000467,28813,787Mar 08 07:45 PM
EASTHAM KARINDirectorMar 05Option Exercise71.092,000142,18015,288Mar 06 07:17 PM
EASTHAM KARINDirectorMar 05Sale229.372,000458,73513,288Mar 06 07:17 PM
Dadswell CharlesSr VP & General CounselMar 05Sale227.1714532,9407,991Mar 06 07:13 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 02Sale222.661,329295,91628,467Mar 05 09:03 PM
BOWMAN A BLAINEDirectorMar 01Option Exercise44.513,000133,53019,868Mar 05 08:12 PM
BOWMAN A BLAINEDirectorMar 01Sale227.013,000681,02816,868Mar 05 08:12 PM
EPSTEIN ROBERT SDirectorFeb 28Sale231.2525057,8137,088Mar 02 07:06 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 16Sale228.851,408322,22113,617Feb 20 09:26 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 15Option Exercise0.002,124015,760Feb 20 09:26 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 15Option Exercise0.006,257032,430Feb 20 09:23 PM
Ronaghi MostafaSr VP & CTOFeb 15Option Exercise0.004,740072,785Feb 20 09:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 15Option Exercise0.006,257032,355Feb 20 09:16 PM
FLATLEY JAY TDirectorFeb 15Option Exercise0.0026,5420413,706Feb 20 09:13 PM
deSouza Francis APresident and CEOFeb 15Option Exercise0.0010,238092,990Feb 20 09:10 PM
Dadswell CharlesSr VP & General CounselFeb 15Option Exercise0.003,79209,455Feb 20 09:07 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 06Sale216.872,000433,74126,052Feb 08 06:23 PM
Dadswell CharlesSr VP & General CounselFeb 05Sale221.451,610356,5355,581Feb 05 07:07 PM
BOWMAN A BLAINEDirectorFeb 01Option Exercise44.513,000133,53019,868Feb 05 07:05 PM
BOWMAN A BLAINEDirectorFeb 01Sale230.823,000692,44816,868Feb 05 07:05 PM
EPSTEIN ROBERT SDirectorJan 29Option Exercise51.171,00051,1708,588Jan 30 08:36 PM
EPSTEIN ROBERT SDirectorJan 29Sale244.181,250305,2257,338Jan 30 08:36 PM
Stapley MarcEVP Strategy & Corp DevelopmtJan 17Sale242.332,000484,66728,315Jan 18 07:01 PM
FLATLEY JAY TDirectorJan 16Sale243.7215,0003,655,763437,899Jan 18 06:50 PM
Dadswell CharlesSr VP & General CounselJan 03Sale224.5014532,5537,411Jan 04 06:53 PM
FLATLEY JAY TDirectorJan 02Sale223.4020,0004,468,090452,899Jan 03 09:16 PM
EPSTEIN ROBERT SDirectorDec 29Option Exercise51.171,00051,1708,838Jan 02 08:36 PM
EPSTEIN ROBERT SDirectorDec 29Sale217.381,250271,7257,588Jan 02 08:36 PM
FLATLEY JAY TDirectorDec 19Sale215.4820,0004,309,502472,899Dec 21 08:03 PM
FLATLEY JAY TDirectorDec 05Sale212.5520,0004,251,088491,717Dec 07 08:21 PM
Stapley MarcEVP Strategy & Corp DevelopmtDec 04Sale219.882,000439,76427,395Dec 06 05:50 PM
Dadswell CharlesSr VP & General CounselDec 04Sale225.3314532,6736,388Dec 06 05:48 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Option Exercise37.043,540131,12226,827Dec 05 05:47 PM
EPSTEIN ROBERT SDirectorDec 01Option Exercise51.171,00051,1709,088Dec 05 05:50 PM
EPSTEIN ROBERT SDirectorDec 01Sale226.551,250283,1887,838Dec 05 05:50 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale226.913,540803,26723,287Dec 05 05:47 PM
FLATLEY JAY TDirectorNov 21Option Exercise70.8215,0001,062,300531,717Nov 24 05:31 PM
FLATLEY JAY TDirectorNov 21Sale211.3520,0004,227,023511,717Nov 24 05:31 PM
Van Oene MarkSVP Chief Commercial OfficerNov 15Sale206.21183,71211,673Nov 15 08:02 PM
Stapley MarcEVP Strategy & Corp DevelopmtNov 15Sale205.482,000410,95829,395Nov 16 05:58 PM
Van Oene MarkSVP Chief Commercial OfficerNov 13Sale207.781,232255,98511,691Nov 15 08:02 PM
FLATLEY JAY TDirectorNov 07Option Exercise70.8220,0001,416,400536,717Nov 08 07:37 PM
FLATLEY JAY TDirectorNov 07Sale210.5920,0004,211,749516,717Nov 08 07:37 PM
Dadswell CharlesSr VP & General CounselNov 03Sale207.881,609334,4797,217Nov 07 08:45 PM
Stapley MarcEVP Strategy & Corp DevelopmtOct 26Sale206.882,000413,75932,679Oct 30 08:00 PM
FLATLEY JAY TDirectorOct 24Option Exercise70.8220,0001,416,400539,176Oct 26 06:51 PM
FLATLEY JAY TDirectorOct 24Sale210.4320,0004,208,568519,176Oct 26 06:51 PM